Engitix Therapeutics Rating A · Worker

Engitix Therapeutics is a biotechnology company specialising in drug discovery for chronic inflammatory diseases, fibrosis, and solid tumours. The company utilises its proprietary platform technology to decode the extracellular matrix, which is the structural scaffolding of human tissue that becomes altered during chronic disease.

By using tissue- and disease-specific human extracellular matrix scaffolds, the company models and studies the biological mechanisms driving these conditions. Engitix Therapeutics develops its own discovery-stage portfolio of therapeutic assets and collaborates with pharmaceutical and biotechnology partners to expand the application of its platform.